# Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma

> **NCT07627698** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 36 (estimated)

## Conditions studied

- Unresectable Melanoma
- Metastatic Cutaneous Melanoma
- Metastatic Uveal Melanoma

## Interventions

- **BIOLOGICAL:** EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07627698
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-06-14
- **Final completion:** 2028-06-17
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07627698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07627698, "Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07627698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*